EA201991409A2 - Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения - Google Patents

Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения

Info

Publication number
EA201991409A2
EA201991409A2 EA201991409A EA201991409A EA201991409A2 EA 201991409 A2 EA201991409 A2 EA 201991409A2 EA 201991409 A EA201991409 A EA 201991409A EA 201991409 A EA201991409 A EA 201991409A EA 201991409 A2 EA201991409 A2 EA 201991409A2
Authority
EA
Eurasian Patent Office
Prior art keywords
pai
antibodies
activator inhibitor
present
plasminogen
Prior art date
Application number
EA201991409A
Other languages
English (en)
Other versions
EA201991409A3 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991409A2 publication Critical patent/EA201991409A2/ru
Publication of EA201991409A3 publication Critical patent/EA201991409A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении представлены антитела, специфически связывающиеся с ингибитором активатора плазминогена 1 типа (PAI-1). В настоящем изобретении также представлены фармацевтические композиции, а также нуклеиновые кислоты, кодирующие антитела к PAI-1, рекомбинантные векторы экспрессии и клетки-хозяева для получения таких антител или их фрагментов. Также представлены способы применения антител для модулирования активности PAI-1 или обнаружения PAI-1 in vitro либо in vivo. В настоящем изобретении дополнительно представлены способы получения антител, специфически связывающихся с PAI-1 в активном конформационном состоянии.
EA201991409A 2014-05-22 2014-08-13 Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения EA201991409A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14305757 2014-05-22

Publications (2)

Publication Number Publication Date
EA201991409A2 true EA201991409A2 (ru) 2019-11-29
EA201991409A3 EA201991409A3 (ru) 2020-01-31

Family

ID=50846892

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991409A EA201991409A3 (ru) 2014-05-22 2014-08-13 Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения

Country Status (10)

Country Link
EP (2) EP3620472A1 (ru)
AU (1) AU2014306649A1 (ru)
CA (1) CA2920890A1 (ru)
EA (1) EA201991409A3 (ru)
IL (1) IL244018A0 (ru)
MA (2) MA38828A1 (ru)
SG (1) SG11201600928SA (ru)
TW (3) TWI592426B (ru)
UY (1) UY35703A (ru)
WO (1) WO2015023752A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017010796A1 (ko) * 2015-07-13 2017-01-19 김동구 정자의 성 감별용 항체 및 이의 용도
KR101916959B1 (ko) * 2015-07-13 2018-11-08 김동구 정자의 성 감별용 항체 및 이의 용도
CN115960235A (zh) * 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
CA3008686C (en) 2015-12-18 2023-03-14 Talengen International Limited Method for preventing and treating diabetic nephropathy
CN106890323A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗肝组织损伤及其相关病症的方法
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
CN108463236A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗放射性和化学性损伤的方法
CA3008186A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Novel method for preventing and treating angiocardiopathy
CN108210905A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗皮肤纤维化的药物及其用途
CN110191718A (zh) 2016-12-15 2019-08-30 泰伦基国际有限公司 一种预防和治疗组织器官纤维化的方法
JP7214225B2 (ja) 2016-12-15 2023-01-30 タレンゲン インターナショナル リミテッド 脂肪肝を予防および治療するための方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
AU660297B2 (en) 1990-11-09 1995-06-22 Stephen D. Gillies Cytokine immunoconjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JP2001506967A (ja) 1996-08-02 2001-05-29 ブリストル―マイヤーズ・スクイブ・カンパニー 治療およびインビボ診断における免疫グロブリンの使用の結果としての免疫グロブリン誘発毒性の抑制方法
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002034776A2 (en) 2000-10-26 2002-05-02 K.U.Leuven Research And Development Epitopes of pai-1
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
SI1562972T1 (sl) 2002-10-15 2010-12-31 Facet Biotech Corp ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CZ294996B6 (cs) 2003-07-16 2005-04-13 Ústav Makromolekulární Chemie Av Čr Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
KR101149242B1 (ko) 2004-01-12 2012-05-25 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Ｆｃ 영역 변이체
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2006019447A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CN101061984B (zh) 2006-04-29 2012-02-08 香港理工大学 利用肌电信号提供机械帮助的康复机器人***
WO2009032661A1 (en) 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
US7771720B2 (en) 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2566514A4 (en) * 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES

Also Published As

Publication number Publication date
TW201722994A (zh) 2017-07-01
EP3620472A1 (en) 2020-03-11
IL244018A0 (en) 2016-04-21
TWI592426B (zh) 2017-07-21
TW201520229A (zh) 2015-06-01
TW201734054A (zh) 2017-10-01
EA201991409A3 (ru) 2020-01-31
CA2920890A1 (en) 2015-02-19
MA44593A1 (fr) 2019-12-31
SG11201600928SA (en) 2016-03-30
UY35703A (es) 2015-03-27
AU2014306649A1 (en) 2016-03-17
WO2015023752A1 (en) 2015-02-19
EP3033359B1 (en) 2019-11-06
MA44593B1 (fr) 2020-06-30
EP3033359A1 (en) 2016-06-22
MA38828A1 (fr) 2018-01-31

Similar Documents

Publication Publication Date Title
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
EA202091710A1 (ru) Антитела против cd73 и способы их применения
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
EA201491644A1 (ru) Фармацевтические композиции
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
AR115389A1 (es) Anticuerpo antagonista de cd73
EA201792047A1 (ru) Новые соединения
EA201891291A1 (ru) Мультиспецифические антитела
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA201591898A1 (ru) Антитела, направленные на m-csf
EA201791437A1 (ru) Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
EA201892804A1 (ru) Антитела против tim-3 и способы их применения
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
AR097319A1 (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
EA201270708A1 (ru) Фармацевтические композиции, содержащие антитела к нейропептидному активатору головы, и их способы